SK-MEL-30

Cat.No.: CSC-C0302

Species: Homo sapiens (Human)

Morphology: adherent, epithelial-like cells growing as monolayers

Culture Properties: monolayer

  • Specification
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0302
Description
Derived from tumor tissue (subcutis metastasis) of a 67-year-old Caucasian man with malignant melanoma in 1975
Species
Homo sapiens (Human)
Recommended Medium
Culture Properties
monolayer
Morphology
adherent, epithelial-like cells growing as monolayers
STR DNA Profile
Amelogenin: X, Y D5S818: 9, 12 D13S317: 8, 11 D7S820: 8, 9 D16S539: 8, 11 vWA: 15, 17 TH01: 6, 6 TPOX: 8, 11 CSF1PO: 10, 10 D19S433: 14, 15 D21S11: 29, 31.2 D18S51: 13, 15 D6S1043: 12 D3S1358: 15, 16 Penta D: 12 D2S441: 10 D8S1179 8, 14 Penta E: 5, 14 D12S391: 18, 21 D2S1338: 19, 21 FGA: 20, 21
Karyotype
Human hypertriploid karyotype with 3.5% polyploidy - 80(69-83)<3n>XXY-Y/XXYY, +1, +1, +2, +2, +3, +7, +10, -11, +12, +17, +18, +20, -21, +2mar, inv(6)(p11;q25), der(7)t(7;14)(p22;q22), der(9)t(9;?21)(p11;q11)x2, 14p+, der(15)t(15;?)(p12;?)x2, der(16)t(16;
Disease
Cutaneous Melanoma
Quality Control
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: cytokeratin -, desmin -, endothel -, GFAP -, HMB-45 +, neurofilament -, vimentin +
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 1 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
SK-Mel-30; SK Mel 30; SKMEL-30; Sk Mel30; SKMEL30; AW-Mel
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Growth Hormone Upregulates Melanoma Drug Resistance and Migration via Melanoma-Derived Exosomes

Cancers | DOI | Paper |

Background

This study investigates how growth hormone (GH) modulates melanoma-derived exosomes to promote drug resistance and migration. Melanoma cells were treated with GH, doxorubicin, and the GHR antagonist pegvisomant. GH-treated cells released exosomes enriched with ABC transporters ABCC1 and ABCB1, N-cadherin, and MMP2, which enhanced drug resistance and migration in recipient melanoma cells. Blocking GHR with pegvisomant reduced these exosomal cargoes, restored drug sensitivity, and attenuated migration. The findings reveal a novel mechanism by which GH drives chemoresistance and metastasis via exosomes and suggest GHR antagonism as a potential therapeutic strategy.

Key Findings

The study demonstrates that growth hormone (GH) promotes chemoresistance and migration in melanoma by altering exosomal cargo. GH treatment increased exosomal levels of ABC transporters ABCC1 and ABCB1, N-cadherin, and MMP2. Exosomes from GH-treated melanoma cells reduced drug retention and increased doxorubicin IC50 in recipient cells, indicating enhanced drug resistance. They also promoted recipient cell migration. The GHR antagonist pegvisomant reversed these effects: exosomes from cells treated with GH, doxorubicin, and pegvisomant had lower levels of these proteins, restored drug sensitivity, and attenuated migration. Blocking autocrine/paracrine GH also suppressed doxorubicin-induced exosomal ABC transporters. These findings identify a novel role for GH in packaging drug efflux pumps and EMT markers into exosomes, and suggest GHR antagonism as a strategy to overcome exosome-mediated chemoresistance in melanoma.

Contribution

Creative Bioarray contributed the SK-MEL-30 human melanoma cell line (Shirley, NY, USA) used in this study. This cell line was essential for exosome isolation, drug retention, chemosensitivity, migration assays, and western blot analyses, enabling the investigation of GH-mediated exosomal cargo and drug resistance across multiple melanoma models.

GH elevates ABC efflux pump levels in melanoma tumor-derived exosomes and corresponding recipient cells.
Fig. 1. GH elevates ABC efflux pump levels in melanoma tumor-derived exosomes and corresponding recipient cells.

Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma

Cancers | DOI | Paper |

Background

This study investigates how growth hormone (GH) promotes chemoresistance in GH receptor-positive human melanoma by upregulating melanocyte-inducing transcription factor (MITF). Using multiple melanoma cell lines, mouse xenografts, and public cancer datasets, the authors show that anticancer drugs increase GH/GHR and MITF expression. GH directly elevates MITF and MITF target genes, enhances melanogenesis and tyrosinase activity, and supports drug clearance pathways. Inhibitor analyses identify JAK2-STAT5 and SRC signaling as key mediators. The findings implicate the GH–GHR axis in melanoma therapy resistance and suggest GHR antagonism as a potential combinatorial strategy.

Key Findings

GH treatment significantly upregulated MITF and MITF target genes in human melanoma cells following chemotherapy, BRAF inhibitors, and tyrosine kinase inhibitors. GH also increased MITF-regulated melanogenesis and tyrosinase activity in multiple cell lines. In B16F10 mouse melanoma xenografts, bovine GH transgenic mice showed elevated MITF and target gene expression versus wild-type littermates. Pathway inhibitor analysis showed that JAK2-STAT5 and SRC activities were critical for GH-induced MITF regulation, with MAPK/ERK involvement under chemotherapy. GHR knockdown suppressed MITF, MITF targets, melanogenesis, and tyrosinase activity, sensitizing cells to drug effects. Bioinformatics analyses across GTEx, NCI60, CCLE, and TCGA datasets corroborated coexpression and correlation of GHR, MITF, and MITF targets. The study provides in vitro, in vivo, and in silico evidence that the GH–GHR axis drives MITF-regulated and ABC-transporter-mediated drug clearance, contributing to melanoma chemoresistance.

Contribution

Creative Bioarray provided the SK-MEL-30 human melanoma cell line used in the in vitro experiments. This cell line enabled the authors to test GH effects on MITF, melanogenesis, tyrosinase activity, and signaling in a BRAF wild-type melanoma context.

GH-regulated MITF and MITF target gene regulation proceeds via JAK2–STAT5- and SRC-regulated pathways
Fig. 2. GH-regulated MITF and MITF target gene regulation proceeds via JAK2–STAT5- and SRC-regulated pathways

Growth Hormone Upregulates Mediators of Melanoma Drug Efflux and Epithelial-to-Mesenchymal Transition In Vitro and In Vivo

Cancers | DOI | Paper |

Background

This study investigates the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) on melanoma progression and therapy resistance. Using mouse B16-F10 and human SK-MEL-30 melanoma cells in vitro, plus syngeneic B16-F10 tumors in bovine GH transgenic (bGH) and GH receptor knockout (GHRKO) mice in vivo, the authors examined tumor growth, multidrug efflux pumps, and epithelial-to-mesenchymal transition (EMT) markers. GH treatment enhanced melanoma cell growth, drug retention, and invasion in vitro, while elevated GH upregulated drug efflux pumps and EMT markers independent of IGF-1 in vivo, revealing GH-driven intrinsic therapy resistance in melanoma.

Key Findings

GH enhanced mouse and human melanoma cell growth, drug retention, and invasion in vitro. In syngeneic models, elevated GH did not accelerate tumor size but significantly upregulated multiple ATP-binding cassette (ABC) drug-efflux pumps. GH specifically elevated Abcb1a, Abcb8, Abcg1, and Abcg2 transporters in an IGF-1-independent manner, whereas IGF-1 upregulated Abcc-type transporters, suggesting distinct and overlapping roles. Additionally, epithelial-to-mesenchymal transition (EMT) transcription markers (Zeb1, Snai1) were significantly upregulated in vivo with Cdh1 suppression, and both GH and IGF-1 proved potent EMT inducers. Combined with GHR knockdown reducing cell growth, these results provide the first in vivo validation that GH drives an intrinsic drug-resistance and metastatic phenotype in melanoma, supporting GHR antagonism as a potential therapeutic strategy alongside chemotherapy.

Contribution

Creative Bioarray provided the SK-MEL-30 human melanoma cell line (CSC-C0302) used in this study. These cells served as the key human melanoma model for assessing GH-induced signaling, ABC drug-efflux pump expression, EMT markers, proliferation, and invasion in vitro, complementing the mouse B16-F10 cells.

Changes in ABC efflux pumps in B16-F10 mouse melanoma in vitro and in vivo.
Fig. 3. Changes in ABC efflux pumps in B16-F10 mouse melanoma in vitro and in vivo.

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products